Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | CASR | P41180 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3676588 | 0.83 | — | — | |
| SCHEMBL7781721 | 0.82 | CYP19A1 (0.33) | CYP19A1 | |
| SCHEMBL3680927 | 0.78 | TNFRSF1A (0.32) | — | |
| SCHEMBL3676072 | 0.78 | CA1 (0.33) | CA1CA2 | |
| SCHEMBL3683598 | 0.78 | — | — | |
| SCHEMBL3677168 | 0.77 | TNFRSF1A (0.31) | — | |
| SCHEMBL3680618 | 0.77 | — | — | |
| SCHEMBL3675854 | 0.76 | — | — | |
| SCHEMBL3676820 | 0.72 | NR3C1 (0.35) | HTR2CHTR2AHTR2BCASRMEN1 | |
| SCHEMBL3680622 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1785429-B1 | PROCESS FOR PRODUCING METALLOCENE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2012-10-03 | — | — | EP | disclosed |
| US-7652159-B2 | Process for producing metallocene compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-01-26 | — | — | US | disclosed |
| US-20080319213-A1 | Process For Producing Metallocene Compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-12-25 | — | — | US | disclosed |
| EP-1785429-A1 | PROCESS FOR PRODUCING METALLOCENE COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2007-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319213-A1 | Process For Producing Metallocene Compound | H1-10, CNOT9, H1-4 | HTR2C 2844/4885HTR2A 2218/4885HTR2B 1991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.